Verona Pharma(VRNA) - 2023 Q4 - Earnings Call Presentation

March 2024 Ensifentrine is an investigational drug and has not been approved by the FDA (or any other regulatory authority). Nasdaq: VRNA | www.veronapharma.com Developing innovative therapies for the treatment of respiratory diseases Forward-looking statements This presentation contains "forward‐looking" statements that are based on the beliefs and assumptions and on information currently available to management of Verona Pharma plc (together with its consolidated subsidiaries, the "Company"). All statemen ...